Histoplasmosis in Africa: An emerging or a neglected disease?

Histoplasmosis in Africa has markedly increased since the advent of the HIV/AIDS epidemic but is under-recognised. Pulmonary histoplasmosis may be misdiagnosed as tuberculosis (TB). In the last six decades (1952-2017), 470 cases of histoplasmosis have been reported. HIV-infected patients accounted f...

Full description

Bibliographic Details
Main Authors: Rita O Oladele, Olusola O Ayanlowo, Malcolm D Richardson, David W Denning
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://doi.org/10.1371/journal.pntd.0006046
id doaj-c3891516b2be465d86dbdf07c89713b8
record_format Article
spelling doaj-c3891516b2be465d86dbdf07c89713b82021-06-18T04:35:14ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352018-01-01121e000604610.1371/journal.pntd.0006046Histoplasmosis in Africa: An emerging or a neglected disease?Rita O OladeleOlusola O AyanlowoMalcolm D RichardsonDavid W DenningHistoplasmosis in Africa has markedly increased since the advent of the HIV/AIDS epidemic but is under-recognised. Pulmonary histoplasmosis may be misdiagnosed as tuberculosis (TB). In the last six decades (1952-2017), 470 cases of histoplasmosis have been reported. HIV-infected patients accounted for 38% (178) of the cases. West Africa had the highest number of recorded cases with 179; the majority (162 cases) were caused by Histoplasma capsulatum var. dubuosii (Hcd). From the Southern African region, 150 cases have been reported, and the majority (119) were caused by H. capsulatum var. capsulatum (Hcc). There have been 12 histoplasmin skin test surveys with rates of 0% to 35% positivity. Most cases of Hcd presented as localised lesions in immunocompetent persons; however, it was disseminated in AIDS patients. Rapid diagnosis of histoplasmosis in Africa is only currently possible using microscopy; antigen testing and PCR are not available in most of Africa. Treatment requires amphotericin B and itraconazole, both of which are not licensed or available in several parts of Africa.https://doi.org/10.1371/journal.pntd.0006046
collection DOAJ
language English
format Article
sources DOAJ
author Rita O Oladele
Olusola O Ayanlowo
Malcolm D Richardson
David W Denning
spellingShingle Rita O Oladele
Olusola O Ayanlowo
Malcolm D Richardson
David W Denning
Histoplasmosis in Africa: An emerging or a neglected disease?
PLoS Neglected Tropical Diseases
author_facet Rita O Oladele
Olusola O Ayanlowo
Malcolm D Richardson
David W Denning
author_sort Rita O Oladele
title Histoplasmosis in Africa: An emerging or a neglected disease?
title_short Histoplasmosis in Africa: An emerging or a neglected disease?
title_full Histoplasmosis in Africa: An emerging or a neglected disease?
title_fullStr Histoplasmosis in Africa: An emerging or a neglected disease?
title_full_unstemmed Histoplasmosis in Africa: An emerging or a neglected disease?
title_sort histoplasmosis in africa: an emerging or a neglected disease?
publisher Public Library of Science (PLoS)
series PLoS Neglected Tropical Diseases
issn 1935-2727
1935-2735
publishDate 2018-01-01
description Histoplasmosis in Africa has markedly increased since the advent of the HIV/AIDS epidemic but is under-recognised. Pulmonary histoplasmosis may be misdiagnosed as tuberculosis (TB). In the last six decades (1952-2017), 470 cases of histoplasmosis have been reported. HIV-infected patients accounted for 38% (178) of the cases. West Africa had the highest number of recorded cases with 179; the majority (162 cases) were caused by Histoplasma capsulatum var. dubuosii (Hcd). From the Southern African region, 150 cases have been reported, and the majority (119) were caused by H. capsulatum var. capsulatum (Hcc). There have been 12 histoplasmin skin test surveys with rates of 0% to 35% positivity. Most cases of Hcd presented as localised lesions in immunocompetent persons; however, it was disseminated in AIDS patients. Rapid diagnosis of histoplasmosis in Africa is only currently possible using microscopy; antigen testing and PCR are not available in most of Africa. Treatment requires amphotericin B and itraconazole, both of which are not licensed or available in several parts of Africa.
url https://doi.org/10.1371/journal.pntd.0006046
work_keys_str_mv AT ritaooladele histoplasmosisinafricaanemergingoraneglecteddisease
AT olusolaoayanlowo histoplasmosisinafricaanemergingoraneglecteddisease
AT malcolmdrichardson histoplasmosisinafricaanemergingoraneglecteddisease
AT davidwdenning histoplasmosisinafricaanemergingoraneglecteddisease
_version_ 1721373519692955648